PURPOSE

In the present study, we aimed to investigate whether the metabolic parameters on baseline F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) could be used to predict prognosis in peripheral T-cell lymphomas (PTCL).

METHODS

A total of 51 nodal PTCL patients who underwent baseline F-FDG PET/CT were retrospectively evaluated in the present study. Total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUV) were also assessed. Besides, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) was also included. Log-rank test and Cox regression analysis were used to evaluate progression-free survival (PFS) and overall survival (OS).

RESULTS

The median follow-up was 18 months. Patients with low TLG, TMTV, and SUV levels had a significantly better clinical outcome than those with high TLG, TMTV, and SUV levels. The 2-year PFS rates of the high- and low-TMTV groups were 34.62% and 80%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( < 0.001), whereas the corresponding 2-year OS rates were 46.15% and 84.00%, respectively ( = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively, = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively, = 10), intermediate-risk group with TMTV > 62.405 or NCCN-IPI score of 4-8 (2-year PFS and OS were 52.4% and 66.7%, respectively.

CONCLUSIONS

Baseline TMTV and TLG were independent predictors of PFS and OS in PTCL patients, and SUV and NCCN-IPI scores were also independent predictors of OS. Moreover, the combination of TMTV and NCCN-IPI scores improved patient risk-stratification at the initial stage and might contribute to the adjustment of the therapeutic regime. This trial is registered with ChiCTR1900025526.